Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Hosted on MSN
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Tryptamine’s phase 1b study of IV-infused psilocin meets all objectives Lead asset TRP-8803 found safe at low, mid and upper dose levels Planning underway to advance TRP-8803 in phase II trials ...
Tryptamine strengthens clinical development team with two key appointments Professor Marcel Mozafari appointed senior formulation scientist and Professor David Castle appointed consultant medical ...
- Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies ...
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation ...
Speculation RFK Jr's appointment to head US Department of Health and Human Services may favourably impact medical psychedelics sector Tryptamine’s lead asset TRP-8803 is an innovative and scalable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results